Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q3 FY2021 Earnings Presentation
25 slides from Camlin Fine Sciences's earnings presentation, Feb 9, 2021
Slide 1: Intimation to BSE and NSE under SEBI LODR Regulation 30
9th February, 2021 To, To, BSE Limited, The Manager, 25, P. J. Towers, Listing Department, Dalal Street, National Stock Exchange of India Ltd., Mumbai – 400 001 Exchange Plaza, Bandra Kurla Complex, Ref: Company Scrip Code: 532834 Bandra (East), Mumbai‐ 400051 Ref: Symbol: CAMLINFINE || Series: EQ S
Slide 2: Earnings Presentation 9M / Q3-FY21
EARNINGS PRESENTATION 9M / Q3-FY21
Slide 3: Snapshot
Snapshot One of the few vertically and backward Leading Manufacturers of Antioxidants in the 3rd largest producer of Vanillin in the integrated players world with more than 30 years of experience world Serving more than 80 countries with over Preferred Partner for manufacturing customized Strategic
Slide 4: About the Company
About the Company • In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror Total Operational Revenue (INR Mn) shareholding) the fine chemical business from Camlin Ltd. 10,491 • The Company has over 30 years of experience providing innovative solutions with a 8,922 8,605 comp
Slide 5: 9M / Q3-FY21 Financial Overview
9M / Q3-FY21 FINANCIAL OVERVIEW
Slide 6: 9M / Q3-FY21 Financial and Operational Highlights
9M / Q3-FY21 Financial and Operational Highlights Q3-FY21 Financial Highlights (Standalone): Q3-FY21 Financial Highlights (Consolidated): INR 1,636 Mn INR 179 Mn 10.94% INR 2,979 Mn INR 468 Mn 15.71% Total Revenue EBITDA EBITDA Margin Total Revenue EBITDA EBITDA Margin INR 203 Mn INR 34 Mn 2.08% INR
Slide 7: Q3-FY21 Standalone Income Statement (Ind-AS)
Q3-FY21 Standalone Income Statement (Ind-AS) Income Statement (Mn) Q3-FY21 Q3-FY20 Y-o-Y Q2-FY21 Q-o-Q Operational Revenue 1,636 1,532 6.8% 1,468 11.4% Total Expenses 1,457 1,392 4.7% 1,397 4.3% Operational EBITDA 179 140 27.9% 71 152.1% Operational EBITDA Margins (%) 10.94% 9.14% 180 Bps 4.84% 610
Slide 8: 9M-FY21 Standalone Income Statement (Ind-AS)
9M-FY21 Standalone Income Statement (Ind-AS) Income Statement (Mn) 9M-FY21 9M-FY20 Y-o-Y Operational Revenue 4,316 4,402 (2.0)% Total Expenses 3,904 3,945 (1.0)% Operational EBITDA 412 457 (9.8)% Operational EBITDA Margins (%) 9.55% 10.38% (83) Bps Adjusted EBITDA* 510 457 11.6% Adjusted EBITDA Marg
Slide 9: Q3-FY21 Consolidated Income Statement (Ind-AS)
Q3-FY21 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) Q3-FY21 Q3-FY20 Y-o-Y Q2-FY21 Q-o-Q Operational Revenue 2,979 2,739 8.8% 2,568 16.0% Total Expenses 2,511 2,444 2.7% 2,232 12.5% Operational EBITDA 468 295 58.6% 336 39.3% Operational EBITDA Margins (%) 15.71% 10.77% 494 Bps 13
Slide 10: 9M-FY21 Consolidated Income Statement (Ind-AS)
9M-FY21 Consolidated Income Statement (Ind-AS) Income Statement (Mn) 9M-FY21 9M-FY20 Y-o-Y Operational Revenue 8,605 7,563 13.8% Total Expenses 7,290 6,606 10.4% Operational EBITDA 1,315 957 37.4% Operational EBITDA Margins (%) 15.28% 12.65% 263 Bps Adjusted EBITDA* 1,455 964 50.9% Adjusted EBITDA M
Slide 11: Country Overview
COUNTRY OVERVIEW
Slide 12: CFS India
CFS India • R&D Centre at Tarapur that has developed many new Diphenol-downstream products • Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries • Provides technical experti
Slide 13: CFS Mexico
CFS Mexico • Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016 • Primarily manufactures Blends and Additives • Key customer segments: Oil, Poultry, Diary, Rendering,Aqua, Pet food, Swine,Vitamin Pre-mix • Total Market size is ~USD 200 Mn and CFS Mexico enjoys an overall market share
Slide 14: CFS Europe
CFS Europe Performance Chemicals • Acquired the manufacturing facility at Ravenna, Italy in 2011, which provides captive requirements of key raw materials i.e. Hydroquinone and Catechol • Capacity utilization achieved at 95% in FY19 • Considerable growth in EBITDA Margins & Profits due to favourable
Slide 15: CFS Brazil
CFS Brazil Shelf Life Solutions • Formed in 2013 for Blends and the production started in 2015 • Has an application lab in Indaiatuba – Brazil for customizing blends for Shelf-life Extension Solutions. • Handles distribution of bulk antioxidants and vanillin. • Key customer segments: Oil, Poultry, D
Slide 16: CFS Wanglong
CFS Wanglong • CFS along with CFS Europe acquired 51% stake in Ningbo Wanglong Flavours in 2017 which had an operational plant since 2011 • This acquisition makes CFS the 3rd largest producer of Vanillin • Located in Grade 1 Industrial zone in the city of Yuyao Zhejiang Province, China. • It manufac
Slide 17: CFS North America
CFS North America Shelf Life Solutions • Formed in October 2015 as a wholly owned subsidiary Market focus • Food - Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants) • Pet food - Rendering for pet food (natural antioxidants), Rendering for animal feed (synthetic antioxidants)
Slide 18: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW
Slide 19: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY18 FY19 FY20 9M-FY21 Operational Income 4,050 5,481 5,798 4,316 Total Expenses 3,996 5,182 5,201 3,904 EBITDA 54 299 597 412 EBITDA Margin 1.33% 5.46% 10.30% 9.55% Depreciation 91 91 113 127 Finance Cost 236 203 281 226 Other Income 92 13
Slide 20: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY19 FY20 H1-FY21 Particulars (INR Mn) FY19 FY20 H1-FY21 EQUITY 3,474 3,768 4,367 Non-Current Assets 2,733 3,802 3,812 a) Equity Share Capital 121 121 121 a) Property, Plant and Equipment 789 686 2,419 b) Other Equity 3,353 3,647 4,246 b) Capital Work In
Slide 21: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY18 FY19 FY20 9M-FY21 Operational Income 7,228 8,922 10,491 8,605 Total Expenses 7,102 8,235 9,184 7,290 EBITDA 126 687 1,307 1,315 EBITDA Margin 1.74% 7.70% 12.46% 15.28% Depreciation 267 290 328 325 Finance Cost 284 367 431 254 Other I
Slide 22: Consolidated Balance Sheet
Consolidated Balance Sheet PARTICULARS (INR Mn) FY19 FY20 H1-FY21 PARTICULARS (INR Mn) FY19 FY20 H1-FY21 EQUITY 4,303 4,601 5,540 Non-Current Assets 4,143 5,591 5,576 a) Equity Share Capital 121 121 121 a) Property, Plant and Equipment 2,055 2,034 3,738 b) Capital Work In Progress 573 1,761 117 b) O
Slide 23: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) 12,000 10,491 1,500 15.28% 18.00% 8,922 16.00% 10,000 8,605 1,200 12.46% 1,315 14.00% 8,000 7,228 12.00% 900 1,307 5,469 7.70% 10.00% 6,000 600 5.16% 8.00% 4,000 687 6.00% 300 1.74% 4.00% 2,000 282 2.0
Slide 24: Capital Markets
Capital Markets 60% 40% 20% 0% -20% -40% -60% -80% Jan-20 Feb-20 Mar-20 Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Sensex Camlin Price Data (31st December, 2020) INR Shareholding Pattern as on 31st December, 2020 Face Value 1.0 Promoters 21.63% Market Price 122.4 52 Week H/L 133.
Slide 25: Disclaimer
Disclaimer Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all e
Camlin Fine Sciences — Q3 FY2021 Earnings Presentation on 6ix